Regimen Reference Order

GAST – lutetium Lu 177 dotatate (LUTATHERA)

ARIA: GAST – [LUTATHERA]

Planned Course: **Every 8 weeks for 4 doses**
Indication for Use: **Neuroendocrine Tumor Midgut or Pancreatic**

Drug Alert: Radioactive therapy

CVAD: At Provider's Discretion

Proceed with treatment if:

- ***WBC equal to or greater than 2 x 10^9/L***
- ***Platelets equal to or greater than 75 x 10^9/L***
- ***Hemoglobin equal to or greater than 80 g/L***
- ***Creatinine clearance equal to or greater than 50 mL/minute***
  - ❖ **Contact Medical Oncologist if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Instruct patient to start vigorous oral pre-hydration (600 – 900 mL) the morning of treatment **(Self-administered at home)**		

Treatment Regimen – GAST – Lutetium 177 (LUTATHERA)

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
ondansetron	16 mg	Orally 30 minutes prior to amino acid solution
dexamethasone	8 mg	Orally 30 minutes prior to amino acid solution
amino acid solution	lysine 25 g and arginine 25 g in 1000 mL in sterile water	IV over 4 hours starting 30 minutes prior to LUTATHERA® **Nursing Alert*: *Lutetium 177 starts 30 minutes after start of amino acid solution*
lutetium Lu 177 dotatate (LUTATHERA®)	7.4 GBq (200 mCi)	IV over 30 minutes via syringe pump by contralateral intravenous infusion **Nursing Alert*: LUTATHERA® *is run concomitantly with the amino acid solution*
metoclopramide	10 – 20 mg	Orally/IV every 4 hours as needed for nausea and vomiting

In the event of an infusion-related hypersensitivity reaction, refer to the **'Hypersensitivity Reaction Standing Order'**

REQUIRED MONITORING

Prior to each dose

- CBC, serum creatinine, urea, electrolytes and liver enzymes as per Physician Orders

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Remind patient that long acting somatostatin analog (octreotide LAR or lanreotide) be administered on the date provided to them by the medical oncology clinic
- Advise patient to urinate frequently during and after administration of LUTATHERA®
- Nuclear Medicine to review radioactive precautions with patient prior to discharge

ADDITIONAL INFORMATION

- Long-acting somatostatin analogs (e.g. octreotide LAR, lanreotide) should not be administered 7 days prior to or 7 days following LUTATHERA® infusions
- Short-acting somatostatin analogs (e.g. octreotide) required for breakthrough symptoms must be discontinued at least 24 hours prior to LUTATHERA® infusions
- Blood work and physician exam should be completed 2 weeks before next scheduled LUTATHERA® dose
- LUTATHERA® is administered at the Nuclear Medicine department at Health Sciences Centre